相关实验视频
Updated: Jan 14, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
901
在肥胖和多种长期疾病患者中,体重指数和疾病负担的变化
Kamlesh Khunti1, Alex Mourer2, Silvia Capucci2
1Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.
Diabetes, obesity & metabolism
|January 13, 2026
概括
肥胖和多种长期疾病 (MLTCs) 患者的体重减轻显示出混合的结果,影响肥胖相关并发症 (ORCs) 和整体健康. 个性化治疗是关键,考虑到不仅仅是减肥的结果.
科学领域:
- 代谢健康和慢性疾病管理.
- 肥胖和多病症的流行病学.
背景情况:
- 肥胖是多重长期疾病 (MLTCs) 的重要危险因素,也被称为多重疾病.
- 减肥对已经管理MLTC的个体的具体影响尚不清楚.
研究的目的:
- 研究身体质量指数 (BMI) 变化与与肥胖有关的并发症 (ORCs) 的发展之间的关联.
- 评估BMI变化对肥胖和MLTC患者临床和经济结果的影响.
主要方法:
- 一项对肥胖 (BMI ≥30 kg/m2) 的成年人 (≤70岁) 和至少两个ORC的队列研究.
- 体重指数的变化被分类为在四年内具体的百分比增加或减少.
- 考克斯回归和Ghosh-Lin模型用于分析各种结果的危险比率和风险.
主要成果:
- 显著的体重减轻与开发新的ORCs的风险降低有关.
- 与稳定的BMI相比,体重减轻和体重增加都与精神健康状况,住院和死亡率的风险增加有关.
- 体重指数下降与较低的多药性相关.
结论:
- 肥胖和MLTC患者的体重管理产生了有益和有害的结果.
- 治疗策略应该是个性化的,重点是对健康结果的综合评估,而不仅仅是减肥.
相关概念视频
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Drug Dosing: Obese Patients
217
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
217
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
Dimensions of Health and Illness
10.4K
The factors influencing the health-illness continuum can be internal or external and may or may not be under conscious control. They are related to the following eight human dimensions, and each dimension is interrelated to one other.
10.4K
Stress Prevention and Stress Management Techniques IV
224
Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
224

